Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free MGNX Stock Alerts

MacroGenics (MGNX) Financials

MacroGenics logo
$4.71 +0.09 (+1.95%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$4.67 -0.04 (-0.85%)
As of 07/2/2026 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for MacroGenics

Annual Income Statements for MacroGenics

This table shows MacroGenics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -20 -59 -20 -171 -152 -130 -202 -120 -9.06 -67 -75
Consolidated Net Income / (Loss)		 -20 -59 -20 -171 -152 -130 -202 -120 -9.06 -67 -75
Net Income / (Loss) Continuing Operations		 -20 -59 -20 -171 -152 -130 -202 -120 -9.06 -67 -75
Total Pre-Tax Income 		-20 -60 -22 -171 -177 -131 -203 -120 -9.06 -66 -75
Total Operating Income		 -20 -60 -22 -171 -177 -131 -203 -121 -168 -111 -73
Total Gross Profit		 101 92 158 60 64 105 75 149 58 149 150
Total Revenue		 101 92 158 60 64 105 77 152 59 150 150
Operating Revenue		 101 92 158 60 64 105 77 152 59 150 150
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 2.65 3.35 0.62 0.85 0.00
Operating Cost of Revenue		 - - - - - 0.00 2.65 3.35 0.62 0.85 0.00
Total Operating Expenses		 121 152 180 231 241 236 278 270 226 260 222
Selling, General & Admin Expense		 23 30 33 41 46 43 63 59 52 71 39
Research & Development Expense		 98 122 147 191 195 193 215 207 167 177 147
Other Operating Expenses / (Income)		 - - - - - 0.00 0.00 4.03 7.60 11 36
Total Other Income / (Expense), net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.66 159 45 -2.45
Interest Expense		 - - - - - - 0.00 0.00 1.43 1.12 8.51
Interest & Investment Income		 - - - - - - 0.00 0.00 151 36 0.00
Other Income / (Expense), net		 - - - - - - - 1.66 9.69 9.42 6.06
Income Tax Expense		 - - - - - - - 0.00 0.00 0.94 -0.67
Basic Earnings per Share		 - - - ($4.19) ($3.16) ($2.47) ($3.37) ($1.95) ($0.15) ($1.07) ($1.18)
Weighted Average Basic Shares Outstanding		 31.80M 34.69M 36.10M 40.93M 48.08M 52.44M 59.94M 61.43M 61.93M 62.62M 63.16M
Diluted Earnings per Share		 - - - ($4.19) ($3.16) ($2.47) ($3.37) ($1.95) ($0.15) ($1.07) ($1.18)
Weighted Average Diluted Shares Outstanding		 31.80M 34.69M 36.10M 40.93M 48.08M 52.44M 59.94M 61.43M 61.93M 62.62M 63.16M
Weighted Average Basic & Diluted Shares Outstanding		 31.80M 34.69M 36.10M 40.93M 48.08M 52.44M - 61.84M 62.43M 63.09M 63.56M

Quarterly Income Statements for MacroGenics

This table shows MacroGenics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 18 -46 -52 -56 56 -15 -41 -36 17 -14 -37
Consolidated Net Income / (Loss)		 18 -46 -52 -56 56 -15 -41 -36 17 -14 -37
Net Income / (Loss) Continuing Operations		 18 -46 -52 -56 56 -15 -41 -36 17 -14 -37
Total Pre-Tax Income 		14 -40 -55 -56 56 -7.14 -43 -36 17 -13 -38
Total Operating Income		 -36 -49 -54 -58 54 -53 -43 -37 19 -12 -33
Total Gross Profit		 10 11 8.83 11 111 7.67 13 22 73 41 21
Total Revenue		 10 11 9.10 11 111 19 13 22 73 41 21
Operating Revenue		 10 11 9.10 11 111 19 13 22 73 41 21
Total Cost of Revenue		 0.09 0.16 0.27 0.18 0.17 12 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 46 60 63 69 56 61 56 59 54 53 54
Selling, General & Admin Expense		 12 13 15 14 14 28 11 9.30 9.91 9.24 9.71
Research & Development Expense		 30 47 46 52 41 39 40 41 33 34 35
Other Operating Expenses / (Income)		 3.27 - 1.85 2.65 1.70 -6.20 5.40 8.91 12 10 9.53
Total Other Income / (Expense), net		 50 9.69 -1.13 2.52 2.12 46 -0.09 0.61 -1.81 -1.16 -4.89
Interest Expense		 0.00 - 1.13 0.01 0.00 -0.02 0.09 0.80 3.34 4.27 4.89
Other Gains / (Losses), net		 3.06 - 2.69 - - - 1.68 - - - 1.55
Basic Earnings per Share		 $0.28 ($0.75) ($0.84) ($0.89) $0.90 ($0.24) ($0.65) ($0.57) $0.27 ($0.23) ($0.58)
Weighted Average Basic Shares Outstanding		 61.98M 61.93M 62.29M 62.66M 62.74M 62.62M 62.97M 63.14M 63.23M 63.16M 63.45M
Diluted Earnings per Share		 $0.28 ($0.74) ($0.84) ($0.89) $0.90 ($0.24) ($0.65) ($0.57) $0.27 ($0.23) ($0.58)
Weighted Average Diluted Shares Outstanding		 62.24M 61.93M 62.29M 62.66M 62.87M 62.62M 62.97M 63.14M 63.28M 63.16M 63.45M
Weighted Average Basic & Diluted Shares Outstanding		 62.03M 62.43M 62.63M 62.72M 62.76M 63.09M 63.09M 63.21M 63.26M 63.56M 63.56M

Annual Cash Flow Statements for MacroGenics

This table details how cash moves in and out of MacroGenics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 39 -112 128 8.40 -94 55 -58 -15 -7.93 82 -126
Net Cash From Operating Activities		 -14 -44 14 -153 -134 -112 -144 -87 -78 -68 -81
Net Cash From Continuing Operating Activities		 -14 -44 14 -153 -134 -112 -144 -87 -78 -68 -81
Net Income / (Loss) Continuing Operations		 -20 -59 -20 -171 -152 -130 -202 -120 -9.06 -67 -75
Consolidated Net Income / (Loss)		 -20 -59 -20 -171 -152 -130 -202 -120 -9.06 -67 -75
Depreciation Expense		 2.86 7.61 7.23 9.16 12 12 11 12 9.65 7.54 7.17
Amortization Expense		 - - - -0.88 -1.46 -0.26 1.61 0.40 -5.00 -2.81 -1.65
Non-Cash Adjustments To Reconcile Net Income		 7.85 12 15 17 22 21 28 27 -127 -7.53 16
Changes in Operating Assets and Liabilities, net		 -4.23 -4.92 12 -6.58 -16 -15 18 -6.13 53 1.39 -28
Net Cash From Investing Activities		 -152 -70 78 57 -79 -7.79 -37 71 -80 149 -114
Net Cash From Continuing Investing Activities		 -152 -70 78 57 -79 -7.79 -37 71 -80 149 -114
Purchase of Property, Plant & Equipment		 -9.20 -11 -29 -25 -4.29 -5.91 -6.20 -3.62 -1.76 -3.71 -1.91
Purchase of Investments		 -143 -348 -135 -133 -264 -224 -231 -121 -240 -77 -208
Sale of Property, Plant & Equipment		 - - - - - - 0.00 0.00 0.06 40 0.01
Sale and/or Maturity of Investments		 0.00 289 242 214 189 222 201 195 161 190 96
Net Cash From Financing Activities		 204 1.85 35 105 120 174 123 1.66 150 0.96 70
Net Cash From Continuing Financing Activities		 204 1.85 35 105 120 174 123 1.66 150 0.96 70
Issuance of Common Equity		 203 0.00 34 103 119 170 118 1.09 0.62 0.00 0.00
Other Financing Activities, net		 0.94 1.85 1.18 2.25 1.32 3.89 4.96 0.57 150 0.96 70

Quarterly Cash Flow Statements for MacroGenics

This table details how cash moves in and out of MacroGenics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -19 11 -21 3.58 96 3.22 -37 -15 -51 -23 9.30
Net Cash From Operating Activities		 -35 -28 -46 -44 60 -38 -47 -47 -30 43 -36
Net Cash From Continuing Operating Activities		 -35 -28 -46 -44 60 -38 -47 -47 -30 43 -36
Net Income / (Loss) Continuing Operations		 18 -46 -52 -56 56 -15 -41 -36 17 -14 -37
Consolidated Net Income / (Loss)		 18 -46 -52 -56 56 -15 -41 -36 17 -14 -37
Depreciation Expense		 1.95 1.90 1.84 1.81 1.84 2.05 1.77 1.91 1.79 1.71 1.69
Amortization Expense		 -1.87 -1.73 -1.32 -0.94 -0.37 -0.19 -0.18 -0.31 -0.51 -0.64 -0.74
Non-Cash Adjustments To Reconcile Net Income		 -44 5.15 6.17 7.28 6.50 -27 4.79 4.68 3.95 2.98 1.78
Changes in Operating Assets and Liabilities, net		 -8.73 13 -0.15 3.02 -4.11 2.63 -12 -17 -52 53 -1.77
Net Cash From Investing Activities		 -34 39 25 47 36 41 9.90 -38 -20 -66 45
Net Cash From Continuing Investing Activities		 -34 39 25 47 36 41 9.90 -38 -20 -66 45
Purchase of Property, Plant & Equipment		 -0.50 -0.62 -1.46 -1.04 -0.59 -0.62 -0.53 -0.72 -0.43 -0.24 -0.34
Purchase of Investments		 -69 -22 -50 -8.01 -4.89 -14 -7.92 -46 -66 -89 -1.98
Sale and/or Maturity of Investments		 36 62 77 56 41 16 18 8.59 46 23 48
Net Cash From Financing Activities		 50 0.27 0.25 0.63 -0.07 0.16 -0.28 70 - 0.06 -0.21
Net Cash From Continuing Financing Activities		 50 0.27 0.25 0.63 -0.07 0.16 -0.28 70 - 0.06 -0.21
Other Financing Activities, net		 50 0.27 0.25 0.63 -0.07 0.16 -0.28 70 - 0.06 -0.21

Annual Balance Sheets for MacroGenics

This table presents MacroGenics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 359 311 374 332 313 379 335 280 298 262 257
Total Current Assets		 342 284 322 269 240 313 280 222 251 217 220
Cash & Equivalents		 196 84 212 220 126 181 123 109 101 183 57
Short-Term Investments		 143 193 93 13 89 91 120 45 129 19 133
Accounts Receivable		 1.22 2.76 14 30 13 23 10 56 10 4.31 13
Inventories, net		 - - - - - 0.00 4.39 1.45 1.22 0.00 7.91
Prepaid Expenses		 1.81 3.48 3.15 6.68 11 17 21 10 9.95 12 8.75
Plant, Property, & Equipment, net		 15 18 50 57 48 42 38 30 22 18 13
Total Noncurrent Assets		 2.04 9.36 1.60 6.29 25 24 18 29 25 26 24
Other Noncurrent Operating Assets		 2.04 1.37 1.60 6.29 25 24 18 29 25 26 24
Total Liabilities & Shareholders' Equity		 359 311 374 332 313 379 335 280 298 262 257
Total Liabilities		 46 43 75 89 82 83 96 138 146 146 201
Total Current Liabilities		 24 27 50 60 45 51 75 49 56 56 43
Accounts Payable		 2.97 4.00 2.45 4.01 4.31 8.03 16 4.90 6.44 5.01 4.79
Accrued Expenses		 12 16 39 33 27 34 34 29 24 29 22
Current Deferred Revenue		 6.78 5.58 8.25 23 11 4.46 21 9.99 22 16 11
Other Current Liabilities		 2.75 1.59 0.47 0.00 3.02 3.99 4.68 4.73 3.78 4.86 5.18
Total Noncurrent Liabilities		 22 15 25 29 37 32 21 90 90 90 158
Capital Lease Obligations		 - - - - - - - - 30 33 32
Noncurrent Deferred Revenue		 19 15 25 29 9.15 6.93 0.00 59 59 56 56
Other Noncurrent Operating Liabilities		 - - - 0.00 28 25 21 30 0.26 1.97 71
Total Equity & Noncontrolling Interests		 313 269 299 243 231 296 240 142 153 116 56
Total Preferred & Common Equity		 313 269 299 243 231 296 240 142 153 116 56
Total Common Equity		 313 269 299 243 231 296 240 142 153 116 56
Common Stock		 548 562 612 733 873 1,068 1,214 1,236 1,255 1,286 1,300
Retained Earnings		 -234 -293 -312 -490 -642 -772 -974 -1,094 -1,103 -1,170 -1,244
Accumulated Other Comprehensive Income / (Loss)		 -0.01 -0.08 -0.06 -0.00 0.02 -0.01 -0.06 -0.01 -0.01 0.00 0.03

Quarterly Balance Sheets for MacroGenics

This table presents MacroGenics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 340 248 201 264 225 245 271 218
Total Current Assets		 291 203 157 222 182 205 232 183
Cash & Equivalents		 90 80 84 180 146 131 80 67
Short-Term Investments		 167 104 56 21 8.57 46 66 88
Accounts Receivable		 25 7.22 6.19 8.75 11 13 69 10
Inventories, net		 1.07 1.25 1.12 3.24 9.43 9.28 8.75 9.50
Prepaid Expenses		 8.51 9.87 9.27 9.84 7.98 6.65 7.71 8.37
Plant, Property, & Equipment, net		 23 21 20 19 17 15 14 11
Total Noncurrent Assets		 26 24 24 23 26 25 25 24
Other Noncurrent Operating Assets		 26 24 24 23 26 25 25 24
Total Liabilities & Shareholders' Equity		 340 248 201 264 225 245 271 218
Total Liabilities		 146 142 143 144 145 199 204 197
Total Current Liabilities		 51 56 58 59 55 39 44 96
Accounts Payable		 3.30 11 5.24 6.61 6.62 4.66 5.94 4.29
Accrued Expenses		 25 18 24 25 28 21 23 18
Current Deferred Revenue		 19 23 24 23 16 7.87 10 68
Other Current Liabilities		 3.93 4.09 4.41 4.74 5.37 5.12 5.14 5.21
Total Noncurrent Liabilities		 95 86 85 85 90 160 159 101
Capital Lease Obligations		 30 30 30 29 32 32 32 31
Noncurrent Deferred Revenue		 64 56 56 56 56 56 56 0.00
Other Noncurrent Operating Liabilities		 0.26 0.26 0.26 0.26 1.97 72 72 69
Total Equity & Noncontrolling Interests		 194 106 58 120 79 47 67 21
Total Preferred & Common Equity		 194 106 58 120 79 47 67 21
Total Common Equity		 194 106 58 120 79 47 67 21
Common Stock		 1,251 1,261 1,268 1,274 1,290 1,294 1,297 1,302
Retained Earnings		 -1,057 -1,155 -1,211 -1,154 -1,211 -1,247 -1,230 -1,281
Accumulated Other Comprehensive Income / (Loss)		 -0.03 -0.04 -0.02 0.01 -0.00 -0.01 0.01 -0.03

Annual Metrics And Ratios for MacroGenics

This table displays calculated financial ratios and metrics derived from MacroGenics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 34,312,353.00 34,835,724.00 36,822,710.00 42,259,080.00 48,917,095.00 56,204,015.00 61,258,001.00 61,475,221.00 62,029,447.00 - 63,258,532.00
DEI Adjusted Shares Outstanding		 34,312,353.00 34,835,724.00 36,822,710.00 42,259,080.00 48,917,095.00 56,204,015.00 61,258,001.00 61,475,221.00 62,029,447.00 - 63,258,532.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.59 -1.68 -0.53 -4.06 -3.10 -2.31 -3.30 -1.95 -0.15 - -1.18
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 111.00% -8.90% 71.68% -61.89% 6.76% 63.40% -26.16% 96.19% -61.33% 155.26% -0.31%
EBITDA Growth		 52.54% -202.75% 71.55% -992.37% -2.09% 28.24% -59.12% 43.41% -43.19% 37.35% 36.47%
EBIT Growth		 47.33% -197.50% 63.12% -673.18% -3.49% 26.03% -54.73% 40.95% -32.40% 36.20% 33.98%
NOPAT Growth		 47.33% -197.50% 63.12% -673.18% -3.49% 26.03% -54.73% 40.13% -38.57% 34.28% 34.13%
Net Income Growth		 47.43% -190.61% 66.47% -773.60% 11.46% 14.54% -55.79% 40.75% 92.44% -639.30% -11.43%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 24.58% 21.84% -36.44% 42.14% 92.31% -613.33% -10.28%
Operating Cash Flow Growth		 58.30% -219.74% 132.98% -1,163.76% 12.38% 16.66% -28.54% 39.54% 10.07% 12.57% -18.53%
Free Cash Flow Firm Growth		 11.97% -108.37% 49.82% -425.15% 5.05% 22.24% -14.35% 33.11% -8.41% 14.10% 98.23%
Invested Capital Growth		 29.18% 36.87% 63.75% 270.22% 48.51% 57.03% -117.12% -208.48% -281.06% -12.80% -93.80%
Revenue Q/Q Growth		 2.75% -3.24% 1,403.74% -69.43% 17.15% 35.54% -33.23% 63.40% -51.50% 6.11% 17.14%
EBITDA Q/Q Growth		 -105.10% -12.62% 90.35% -807.67% 0.44% 23.55% -41.59% 39.94% -54.62% 7.34% 42.88%
EBIT Q/Q Growth		 -90.04% -12.47% 86.36% -597.09% 1.68% 21.78% -38.21% 37.51% -48.31% 5.54% 41.20%
NOPAT Q/Q Growth		 -90.04% -12.47% 86.36% -597.09% 1.68% 21.78% -38.21% 36.64% -10.16% -3.25% 35.87%
Net Income Q/Q Growth		 -88.10% -12.13% 87.74% -713.23% 8.58% 17.91% -38.26% 37.16% -118.18% 31.40% 1.67%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 11.24% 20.83% -41.60% 37.10% -118.99% 31.85% 0.84%
Operating Cash Flow Q/Q Growth		 -41.27% -10.57% 111.45% -982.08% -8.76% 22.51% -51.31% 49.02% -275.12% -17.88% 50.12%
Free Cash Flow Firm Q/Q Growth		 -17.18% -3.46% 77.22% -151.96% -23.42% 21.35% -35.91% 51.47% -42.56% -26.81% 98.47%
Invested Capital Q/Q Growth		 2.76% -15.75% 58.52% -55.50% 1,801.79% 113.74% 46.41% -175.46% -45.64% -4.07% -116.16%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 96.58% 97.79% 98.95% 91.80% 100.00%
EBITDA Margin		 -17.17% -57.07% -9.46% -271.00% -259.15% -113.81% -245.24% -70.74% -261.99% -64.30% -40.98%
Operating Margin		 -20.01% -65.35% -14.04% -284.77% -276.04% -124.96% -261.85% -79.91% -286.38% -73.74% -48.72%
EBIT Margin		 -20.01% -65.35% -14.04% -284.77% -276.04% -124.96% -261.85% -78.82% -269.89% -67.46% -44.67%
Profit (Net Income) Margin		 -19.97% -63.70% -12.44% -285.18% -236.51% -123.70% -260.97% -78.82% -15.42% -44.66% -49.91%
Tax Burden Percent		 99.79% 97.48% 88.63% 100.14% 85.68% 98.99% 99.66% 100.00% 100.00% 101.43% 99.11%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 5.71% 65.27% 112.74%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -5,802.19% -996.78% -480.01% -1,466.87% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -5,783.00% -984.40% -464.45% -1,443.56% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 5,738.94% 932.66% 430.73% 1,391.39% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -9.27% -20.11% -6.91% -63.25% -64.12% -49.28% -75.49% -62.76% -6.15% -49.85% -86.95%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -1,355.51% -1,035.82% -524.38% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -7.57% -17.91% -6.46% -48.50% -54.97% -37.92% -56.81% -38.90% -54.78% -36.12% -25.76%
Return on Assets (ROA)		 -7.56% -17.46% -5.73% -48.57% -47.10% -37.54% -56.62% -38.90% -3.13% -23.91% -28.78%
Return on Common Equity (ROCE)		 -9.27% -20.11% -6.91% -63.25% -64.12% -49.28% -75.49% -62.76% -6.15% -49.85% -86.95%
Return on Equity Simple (ROE_SIMPLE)		 -6.43% -21.78% -6.56% -70.59% -65.83% -43.85% -84.35% -84.33% 0.00% -57.70% 0.00%
Net Operating Profit after Tax (NOPAT)		 -14 -42 -16 -120 -124 -92 -142 -85 -118 -77 -51
NOPAT Margin		 -14.01% -45.74% -9.83% -199.34% -193.23% -87.47% -183.30% -55.94% -200.46% -51.62% -34.11%
Net Nonoperating Expense Percent (NNEP)		 -2.42% -5.29% -1.40% -19.19% -12.39% -15.56% -23.31% -17.47% 61.43% 5.66% -14.44%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -59.85% -64.42% -52.07% -58.49%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.42% 2.21% 1.05% 8.20% 0.00%
SG&A Expenses to Revenue		 22.57% 32.47% 20.70% 67.36% 71.76% 40.75% 81.36% 38.80% 88.83% 47.38% 26.19%
R&D to Revenue		 97.44% 132.88% 93.34% 317.40% 304.28% 184.21% 277.06% 136.25% 283.55% 118.16% 98.44%
Operating Expenses to Revenue		 120.01% 165.35% 114.04% 384.77% 376.04% 224.96% 358.43% 177.71% 385.32% 165.54% 148.72%
Earnings before Interest and Taxes (EBIT)		 -20 -60 -22 -171 -177 -131 -203 -120 -159 -101 -67
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -17 -52 -15 -163 -166 -119 -190 -107 -154 -96 -61
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.39 2.65 2.34 2.21 2.31 4.34 4.10 2.90 3.91 1.76 1.83
Price to Tangible Book Value (P/TBV)		 3.39 2.65 2.34 2.21 2.31 4.34 4.10 2.90 3.91 1.76 1.83
Price to Revenue (P/Rev)		 10.54 7.75 4.44 8.93 8.29 12.25 12.70 2.71 10.16 1.36 0.68
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 30.34 21.28 43.35 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 7.17 4.65 2.50 5.05 4.93 9.65 9.55 1.70 6.76 0.23 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 27.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.20 0.28 0.57
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.20 0.28 0.57
Financial Leverage		 -1.14 -1.07 -1.04 -0.99 -0.95 -0.93 -0.96 -1.04 -1.20 -1.37 -1.91
Leverage Ratio		 1.23 1.15 1.21 1.30 1.36 1.31 1.33 1.61 1.96 2.08 3.02
Compound Leverage Factor		 1.23 1.15 1.21 1.30 1.36 1.31 1.33 1.61 0.11 1.36 3.41
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 16.52% 21.93% 36.23%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 16.52% 21.93% 36.23%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 83.48% 78.07% 63.77%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.20 -0.34 -0.52
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.30 1.75 2.58
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.20 -0.34 -0.52
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.26 -0.42 -0.62
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.69 2.18 3.11
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.26 -0.42 -0.62
Altman Z-Score		 14.13 9.38 5.56 0.78 0.11 6.42 1.07 -3.80 -3.49 -5.38 -5.93
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 14.15 10.40 6.48 4.49 5.31 6.17 3.75 4.57 4.48 3.92 5.10
Quick Ratio		 14.06 10.25 6.41 4.38 5.06 5.83 3.41 4.33 4.28 3.71 4.72
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -25 -52 -26 -136 -129 -100 -115 -77 -83 -71 -1.26
Operating Cash Flow to CapEx		 -148.54% -383.79% 48.99% -614.07% -3,130.57% -1,894.65% -2,319.46% -2,400.19% -4,600.29% 0.00% -4,258.54%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -58.12 -64.02 -0.15
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -54.69 -61.32 -9.53
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -55.88 -28.63 -9.75
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.38 0.27 0.46 0.17 0.20 0.30 0.22 0.49 0.20 0.54 0.58
Accounts Receivable Turnover		 48.50 46.08 19.23 2.78 3.03 5.86 4.63 4.56 1.76 20.44 16.91
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.15 0.46 0.00 0.00
Fixed Asset Turnover		 9.33 5.60 4.64 1.13 1.22 2.32 1.94 4.52 2.29 7.51 9.73
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.23 0.33 0.11 2.15 0.00
Days Sales Outstanding (DSO)		 7.53 7.92 18.98 131.21 120.34 62.34 78.86 80.00 206.85 17.86 21.59
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 318.00 787.79 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 1,619.92 1,110.96 3,343.97 169.99 0.00
Cash Conversion Cycle (CCC)		 7.53 7.92 18.98 131.21 120.34 62.34 -1,541.06 -712.95 -2,349.32 -152.13 21.59
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -26 -16 -5.88 10 15 23 -4.00 -12 -47 -53 -103
Invested Capital Turnover		 -3.25 -4.38 -14.27 29.11 5.16 5.49 8.00 -18.61 -1.98 -3.00 -1.92
Increase / (Decrease) in Invested Capital		 11 9.48 10 16 4.86 8.48 -27 -8.34 -35 -6.02 -50
Enterprise Value (EV)		 724 427 395 304 316 1,012 740 258 397 35 -56
Market Capitalization		 1,063 712 700 537 532 1,285 983 412 597 204 102
Book Value per Share		 $9.13 $7.71 $8.13 $5.75 $4.71 $5.26 $3.91 $2.31 $2.46 $1.85 $0.88
Tangible Book Value per Share		 $9.13 $7.71 $8.13 $5.75 $4.71 $5.26 $3.91 $2.31 $2.46 $1.85 $0.88
Total Capital		 313 269 299 243 231 296 240 142 183 149 87
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 30 33 32
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 30 33 32
Net Debt		 -339 -285 -305 -233 -216 -273 -244 -154 -200 -169 -158
Capital Expenditures (CapEx)		 9.20 11 29 25 4.29 5.91 6.20 3.62 1.70 -36 1.90
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -21 -20 -33 -24 -21 -11 -39 19 -35 -40 -13
Debt-free Net Working Capital (DFNWC)		 318 257 273 209 195 262 205 174 195 162 177
Net Working Capital (NWC)		 318 257 273 209 195 262 205 174 195 162 177
Net Nonoperating Expense (NNE)		 6.01 16 4.13 52 28 38 60 35 -109 -10 24
Net Nonoperating Obligations (NNO)		 -339 -285 -305 -233 -216 -273 -244 -154 -200 -169 -158
Total Depreciation and Amortization (D&A)		 2.86 7.61 7.23 8.28 11 12 13 12 4.64 4.73 5.52
Debt-free, Cash-free Net Working Capital to Revenue		 -20.69% -22.15% -20.65% -39.39% -32.93% -10.12% -49.88% 12.65% -58.85% -26.48% -8.75%
Debt-free Net Working Capital to Revenue		 315.49% 279.33% 172.78% 347.94% 303.20% 249.73% 264.67% 114.23% 332.31% 108.00% 118.28%
Net Working Capital to Revenue		 315.49% 279.33% 172.78% 347.94% 303.20% 249.73% 264.67% 114.23% 332.31% 108.00% 118.28%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($1.95) ($0.15) ($1.07) ($1.18)
Adjusted Weighted Average Basic Shares Outstanding		 34.53M 34.97M 36.92M 48.78M 48.98M 56.26M 0.00 61.43M 61.93M 62.62M 63.16M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($1.95) ($0.15) ($1.07) ($1.18)
Adjusted Weighted Average Diluted Shares Outstanding		 34.53M 34.97M 36.92M 48.78M 48.98M 56.26M 0.00 61.43M 61.93M 62.62M 63.16M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 31.80M 34.69M 36.10M 40.93M 48.08M 52.44M 0.00 61.84M 62.43M 63.09M 63.56M
Normalized Net Operating Profit after Tax (NOPAT)		 -14 -42 -16 -120 -124 -92 -142 -85 -118 -77 -51
Normalized NOPAT Margin		 -14.01% -45.74% -9.83% -199.34% -193.23% -87.47% -183.30% -55.94% -200.46% -51.62% -34.11%
Pre Tax Income Margin		 -20.01% -65.35% -14.04% -284.77% -276.04% -124.96% -261.85% -78.82% -15.42% -44.03% -50.36%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -110.88 -90.72 -7.85
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -82.36 -69.42 -5.99
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -112.07 -58.03 -8.07
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -83.55 -36.73 -6.22
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for MacroGenics

This table displays calculated financial ratios and metrics derived from MacroGenics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 61,949,474.00 62,029,447.00 62,432,013.00 62,633,460.00 62,722,244.00 - 63,090,323.00 63,090,323.00 63,205,703.00 63,258,532.00 63,555,837.00
DEI Adjusted Shares Outstanding		 61,949,474.00 62,029,447.00 62,432,013.00 62,633,460.00 62,722,244.00 - 63,090,323.00 63,090,323.00 63,205,703.00 63,258,532.00 63,555,837.00
DEI Earnings Per Adjusted Shares Outstanding		 0.28 -0.74 -0.84 -0.89 0.90 - -0.65 -0.57 0.27 -0.22 -0.58
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -75.09% -85.34% -62.83% -17.81% 964.81% 80.53% 44.90% 105.99% -34.21% 113.03% 57.48%
EBITDA Growth		 -61.03% -430.59% -48.61% -26.87% 263.09% -3.64% 22.90% 38.40% -62.89% 78.35% 20.83%
EBIT Growth		 -42.26% -511.87% -39.88% -23.79% 258.61% -7.06% 20.70% 36.50% -64.19% 77.11% 21.55%
NOPAT Growth		 -103.23% -388.31% -39.88% 9.42% 252.64% -7.06% 20.70% 36.82% -65.61% 77.11% 21.55%
Net Income Growth		 170.75% -459.88% -37.31% -196.86% 220.78% 66.53% 21.37% 34.88% -70.13% 8.21% 10.39%
EPS Growth		 170.00% -470.00% -37.70% -196.74% 221.43% 67.57% 22.62% 35.96% -70.00% 4.17% 10.77%
Operating Cash Flow Growth		 -274.08% -195.62% -255.67% -2,029.49% 270.69% -36.99% -2.73% -5.62% -150.17% 212.01% 23.63%
Free Cash Flow Firm Growth		 131.77% -99.43% -202.20% -227.95% 455.78% -26,983.33% 71.22% 172.20% -79.11% 233.22% 200.96%
Invested Capital Growth		 -297.45% -281.06% 63.63% -36.89% -57.86% -12.80% 10.87% -84.76% 6.70% -93.80% -137.02%
Revenue Q/Q Growth		 -20.85% 3.11% -15.07% 18.60% 925.36% -82.52% -31.83% 68.59% 227.50% -43.40% -49.61%
EBITDA Q/Q Growth		 17.97% -38.84% -8.22% -2.93% 205.45% -191.58% 19.49% 17.76% 163.54% -151.46% -194.44%
EBIT Q/Q Growth		 21.04% -39.02% -8.91% -3.55% 201.17% -197.50% 19.33% 17.08% 157.05% -159.98% -176.47%
NOPAT Q/Q Growth		 21.04% 2.69% -8.91% -8.24% 233.06% -168.25% 19.33% 13.76% 172.43% -145.43% -176.47%
Net Income Q/Q Growth		 -69.45% -362.46% -13.28% -6.66% 201.16% -127.39% -166.10% 11.66% 146.40% -184.15% -159.80%
EPS Q/Q Growth		 -69.57% -364.29% -13.51% -5.95% 201.12% -126.67% -170.83% 12.31% 147.37% -185.19% -152.17%
Operating Cash Flow Q/Q Growth		 -1,587.22% 20.45% -62.80% 2.54% 235.24% -163.84% -22.09% -0.20% 35.75% 242.52% -183.24%
Free Cash Flow Firm Q/Q Growth		 -36.63% -99.12% -105,878.65% 78.28% 375.27% -142.50% -13.24% 154.49% -20.34% 171.02% -14.18%
Invested Capital Q/Q Growth		 16.50% -45.64% -2.47% -9.86% 3.71% -4.07% 19.03% -127.72% 51.37% -116.16% 0.97%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 99.18% 98.48% 97.03% 98.37% 99.85% 39.62% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -340.71% -458.79% -584.62% -507.42% 52.19% -263.37% -311.06% -151.74% 29.44% -26.76% -156.39%
Operating Margin		 -341.46% -460.39% -590.40% -538.86% 48.95% -273.02% -323.10% -165.27% 25.59% -29.34% -160.96%
EBIT Margin		 -341.46% -460.39% -590.40% -515.50% 50.86% -273.02% -323.10% -158.91% 27.68% -29.34% -160.96%
Profit (Net Income) Margin		 168.84% -429.78% -573.26% -515.55% 50.86% -79.68% -311.07% -162.99% 23.09% -34.33% -177.01%
Tax Burden Percent		 121.08% 116.14% 95.09% 100.00% 100.00% 215.89% 96.07% 100.29% 100.00% 106.81% 95.95%
Interest Burden Percent		 -40.84% 80.37% 102.11% 100.01% 100.00% 13.52% 100.21% 102.27% 83.43% 109.57% 114.62%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 31.44% -6.15% -21.58% -118.91% -62.17% -49.85% -60.25% -69.71% -81.13% -86.95% -140.27%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -154.53% -93.45% -86.51% -83.45% 23.78% -146.21% -210.53% -117.79% 13.20% -16.92% -114.29%
Return on Assets (ROA)		 76.41% -87.23% -84.00% -83.45% 23.78% -42.67% -202.69% -120.81% 11.01% -19.80% -125.69%
Return on Common Equity (ROCE)		 31.44% -6.15% -21.58% -118.91% -62.17% -49.85% -60.25% -69.71% -81.13% -86.95% -140.27%
Return on Equity Simple (ROE_SIMPLE)		 25.68% 0.00% -21.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -36 -35 -38 -41 54 -37 -30 -26 19 -8.47 -23
NOPAT Margin		 -341.46% -322.27% -413.28% -377.20% 48.95% -191.12% -226.17% -115.69% 25.59% -20.54% -112.67%
Net Nonoperating Expense Percent (NNEP)		 31.88% -6.51% -7.36% -9.31% 1.07% 11.70% -8.11% -8.25% -1.27% -3.48% -10.91%
Return On Investment Capital (ROIC_SIMPLE)		 - -18.90% -27.65% -46.56% 36.27% -24.88% -26.83% -32.68% 18.85% -9.71% -44.59%
Cost of Revenue to Revenue		 0.82% 1.52% 2.97% 1.63% 0.15% 60.38% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 119.35% 117.16% 161.57% 133.58% 12.74% 143.70% 81.25% 41.82% 13.60% 22.40% 46.74%
R&D to Revenue		 289.80% 441.71% 505.59% 479.13% 36.62% 200.95% 300.92% 183.40% 44.91% 82.41% 168.35%
Operating Expenses to Revenue		 440.65% 558.87% 687.43% 637.23% 50.90% 312.64% 423.10% 265.27% 74.41% 129.34% 260.96%
Earnings before Interest and Taxes (EBIT)		 -36 -49 -54 -56 56 -53 -43 -35 20 -12 -33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -35 -49 -53 -55 58 -51 -41 -34 21 -11 -32
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.49 3.91 8.66 4.60 1.72 1.76 1.01 1.64 1.58 1.83 8.66
Price to Tangible Book Value (P/TBV)		 1.49 3.91 8.66 4.60 1.72 1.76 1.01 1.64 1.58 1.83 8.66
Price to Revenue (P/Rev)		 2.38 10.16 21.20 6.49 1.46 1.36 0.52 0.46 0.83 0.68 1.17
Price to Earnings (P/E)		 5.80 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 17.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.52 6.76 17.64 3.79 0.25 0.23 0.00 0.00 0.00 0.00 0.39
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.26
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.16 0.20 0.28 0.51 0.24 0.28 0.41 0.69 0.48 0.57 1.48
Long-Term Debt to Equity		 0.16 0.20 0.28 0.51 0.24 0.28 0.41 0.69 0.48 0.57 1.48
Financial Leverage		 -1.05 -1.20 -1.84 -1.40 -1.27 -1.37 -1.49 -2.44 -1.53 -1.91 -2.44
Leverage Ratio		 1.69 1.96 2.75 2.21 1.92 2.08 2.55 4.28 2.86 3.02 4.41
Compound Leverage Factor		 -0.69 1.58 2.81 2.21 1.92 0.28 2.56 4.37 2.39 3.31 5.06
Debt to Total Capital		 13.46% 16.52% 21.99% 33.90% 19.65% 21.93% 28.86% 40.80% 32.23% 36.23% 59.62%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 13.46% 16.52% 21.99% 33.90% 19.65% 21.93% 28.86% 40.80% 32.23% 36.23% 59.62%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 86.54% 83.48% 78.01% 66.10% 80.35% 78.07% 71.14% 59.20% 67.77% 63.77% 40.38%
Debt to EBITDA		 -0.30 -0.20 -0.17 -0.15 -0.28 -0.34 -0.34 -0.45 -0.30 -0.52 -0.53
Net Debt to EBITDA		 2.27 1.30 0.85 0.57 1.64 1.75 1.30 2.02 1.07 2.58 2.09
Long-Term Debt to EBITDA		 -0.30 -0.20 -0.17 -0.15 -0.28 -0.34 -0.34 -0.45 -0.30 -0.52 -0.53
Debt to NOPAT		 -0.28 -0.26 -0.23 -0.22 -0.39 -0.42 -0.46 -0.59 -0.40 -0.62 -0.70
Net Debt to NOPAT		 2.12 1.69 1.20 0.80 2.28 2.18 1.75 2.64 1.44 3.11 2.76
Long-Term Debt to NOPAT		 -0.28 -0.26 -0.23 -0.22 -0.39 -0.42 -0.46 -0.59 -0.40 -0.62 -0.70
Altman Z-Score		 -2.31 -2.28 -2.46 -7.43 -3.28 -4.77 -6.48 -5.87 -4.50 -5.23 -6.98
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.68 4.48 3.63 2.71 3.75 3.92 3.28 5.26 5.22 5.10 1.90
Quick Ratio		 5.49 4.28 3.43 2.53 3.53 3.71 2.97 4.85 4.85 4.72 1.72
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 13 0.12 -122 -26 73 -31 -35 19 15 41 35
Operating Cash Flow to CapEx		 -7,207.77% -4,522.10% -3,128.38% -4,298.07% 11,750.39% 0.00% -8,863.89% -6,571.33% -7,085.92% 18,463.95% -10,410.17%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -107.55 -4,411.62 0.00 0.00 -385.38 23.83 4.56 9.66 7.24
Operating Cash Flow to Interest Expense		 0.00 0.00 -40.29 -7,414.17 0.00 0.00 -515.27 -58.58 -9.03 10.07 -7.32
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -41.57 -7,586.67 0.00 0.00 -521.09 -59.48 -9.16 10.01 -7.40
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.45 0.20 0.15 0.16 0.47 0.54 0.65 0.74 0.48 0.58 0.71
Accounts Receivable Turnover		 6.19 1.76 2.00 6.51 8.30 20.44 17.35 17.68 3.27 16.91 14.98
Inventory Turnover		 0.53 0.46 0.58 0.54 0.36 0.00 0.11 2.28 1.95 0.00 0.00
Fixed Asset Turnover		 4.43 2.29 1.80 1.84 6.77 7.51 8.07 9.26 7.72 9.73 11.07
Accounts Payable Turnover		 0.14 0.11 0.11 0.15 0.16 2.15 0.07 2.40 1.86 0.00 0.00
Days Sales Outstanding (DSO)		 58.98 206.85 182.59 56.07 43.98 17.86 21.04 20.65 111.51 21.59 24.36
Days Inventory Outstanding (DIO)		 686.61 787.79 624.87 672.67 1,012.32 0.00 3,376.09 159.97 187.33 0.00 0.00
Days Payable Outstanding (DPO)		 2,527.56 3,343.97 3,399.06 2,374.87 2,329.05 169.99 5,475.32 152.32 196.06 0.00 0.00
Cash Conversion Cycle (CCC)		 -1,781.97 -2,349.32 -2,591.60 -1,646.13 -1,272.74 -152.13 -2,078.18 28.30 102.78 21.59 24.36
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -32 -47 -48 -53 -51 -53 -43 -98 -48 -103 -102
Invested Capital Turnover		 -15.21 -1.98 -0.48 -0.90 -3.40 -3.00 -3.38 -2.20 -2.59 -1.92 -2.17
Increase / (Decrease) in Invested Capital		 -49 -35 84 -14 -19 -6.02 5.23 -45 3.41 -50 -59
Enterprise Value (EV)		 62 397 765 155 35 35 -42 -68 -8.34 -56 61
Market Capitalization		 289 597 919 266 206 204 80 76 106 102 184
Book Value per Share		 $3.13 $2.46 $1.70 $0.92 $1.91 $1.85 $1.25 $0.74 $1.06 $0.88 $0.33
Tangible Book Value per Share		 $3.13 $2.46 $1.70 $0.92 $1.91 $1.85 $1.25 $0.74 $1.06 $0.88 $0.33
Total Capital		 224 183 136 87 149 149 111 79 99 87 52
Total Debt		 30 30 30 30 29 33 32 32 32 32 31
Total Long-Term Debt		 30 30 30 30 29 33 32 32 32 32 31
Net Debt		 -226 -200 -154 -111 -171 -169 -122 -144 -115 -158 -123
Capital Expenditures (CapEx)		 0.49 0.62 1.46 1.04 0.51 -39 0.53 0.72 0.43 0.23 0.34
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -16 -35 -37 -41 -37 -40 -27 -11 41 -13 -68
Debt-free Net Working Capital (DFNWC)		 240 195 147 99 163 162 127 166 188 177 87
Net Working Capital (NWC)		 240 195 147 99 163 162 127 166 188 177 87
Net Nonoperating Expense (NNE)		 -53 12 15 15 -2.12 -22 11 11 1.81 5.69 13
Net Nonoperating Obligations (NNO)		 -226 -200 -154 -111 -171 -169 -122 -144 -115 -158 -123
Total Depreciation and Amortization (D&A)		 0.08 0.17 0.53 0.87 1.46 1.87 1.59 1.60 1.28 1.06 0.95
Debt-free, Cash-free Net Working Capital to Revenue		 -13.54% -58.85% -86.32% -100.75% -26.52% -26.48% -17.85% -6.37% 32.30% -8.75% -43.06%
Debt-free Net Working Capital to Revenue		 198.16% 332.31% 338.61% 241.47% 115.25% 108.00% 82.21% 100.27% 147.01% 118.28% 55.12%
Net Working Capital to Revenue		 198.16% 332.31% 338.61% 241.47% 115.25% 108.00% 82.21% 100.27% 147.01% 118.28% 55.12%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.28 ($0.75) ($0.84) ($0.89) $0.90 ($0.24) ($0.65) ($0.57) $0.27 ($0.23) ($0.58)
Adjusted Weighted Average Basic Shares Outstanding		 61.98M 61.93M 62.29M 62.66M 62.74M 62.62M 62.97M 63.14M 63.23M 63.16M 63.45M
Adjusted Diluted Earnings per Share		 $0.28 ($0.74) ($0.84) ($0.89) $0.90 ($0.24) ($0.65) ($0.57) $0.27 ($0.23) ($0.58)
Adjusted Weighted Average Diluted Shares Outstanding		 62.24M 61.93M 62.29M 62.66M 62.87M 62.62M 62.97M 63.14M 63.28M 63.16M 63.45M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 62.03M 62.43M 62.63M 62.72M 62.76M 63.09M 63.09M 63.21M 63.26M 63.56M 63.56M
Normalized Net Operating Profit after Tax (NOPAT)		 -25 -35 -38 -41 38 -37 -30 -26 13 -8.47 -23
Normalized NOPAT Margin		 -239.02% -322.27% -413.28% -377.20% 34.26% -191.12% -226.17% -115.69% 17.91% -20.54% -112.67%
Pre Tax Income Margin		 139.44% -370.04% -602.84% -515.55% 50.86% -36.91% -323.79% -162.52% 23.09% -32.15% -184.49%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -47.44 -9,276.33 0.00 0.00 -468.40 -44.07 6.03 -2.83 -6.84
NOPAT to Interest Expense		 0.00 0.00 -33.21 -6,787.78 0.00 0.00 -327.88 -32.08 5.58 -1.98 -4.79
EBIT Less CapEx to Interest Expense		 0.00 0.00 -48.73 -9,448.83 0.00 0.00 -474.21 -44.96 5.91 -2.89 -6.91
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -34.50 -6,960.28 0.00 0.00 -333.69 -32.97 5.45 -2.04 -4.86
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

MacroGenics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, MacroGenics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

MacroGenics' net income appears to be on an upward trend, with a most recent value of -$74.62 million in 2025, rising from -$20.14 million in 2015. The previous period was -$66.97 million in 2024. See MacroGenics' forecast for analyst expectations on what's next for the company.

MacroGenics' total operating income in 2025 was -$72.84 million, based on the following breakdown:
  • Total Gross Profit: $149.50 million
  • Total Operating Expenses: $222.34 million

Over the last 10 years, MacroGenics' total revenue changed from $100.85 million in 2015 to $149.50 million in 2025, a change of 48.2%.

MacroGenics' total liabilities were at $201.26 million at the end of 2025, a 38.2% increase from 2024, and a 338.2% increase since 2015.

In the past 10 years, MacroGenics' cash and equivalents has ranged from $57.22 million in 2025 to $220.13 million in 2018, and is currently $57.22 million as of their latest financial filing in 2025.

Over the last 10 years, MacroGenics' book value per share changed from 9.13 in 2015 to 0.88 in 2025, a change of -90.4%.


Related Companies

Financial statements for NASDAQ:MGNX last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel